201 related articles for article (PubMed ID: 27447733)
1. Metabolomics Analysis of Hormone-Responsive and Triple-Negative Breast Cancer Cell Responses to Paclitaxel Identify Key Metabolic Differences.
Stewart DA; Winnike JH; McRitchie SL; Clark RF; Pathmasiri WW; Sumner SJ
J Proteome Res; 2016 Sep; 15(9):3225-40. PubMed ID: 27447733
[TBL] [Abstract][Full Text] [Related]
2. Detection of metabolic adaptation in a triple-negative breast cancer animal model with [
Kohan AA; Lupien M; Cescon D; Deblois G; Ventura M; Metser U; Veit-Haibach P
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1261-1267. PubMed ID: 38095672
[TBL] [Abstract][Full Text] [Related]
3. Metabolic reprogramming in triple-negative breast cancer.
Wang Z; Jiang Q; Dong C
Cancer Biol Med; 2020 Feb; 17(1):44-59. PubMed ID: 32296576
[TBL] [Abstract][Full Text] [Related]
4. Disclosing a metabolic signature of cisplatin resistance in MDA-MB-231 triple-negative breast cancer cells by NMR metabolomics.
Carneiro TJ; Carvalho ALMB; Vojtek M; Carmo IF; Marques MPM; Diniz C; Gil AM
Cancer Cell Int; 2023 Dec; 23(1):310. PubMed ID: 38057765
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer.
Wang Y; Sun Y; Wang F; Wang H; Hu J
Biomed Pharmacother; 2023 Dec; 169():115866. PubMed ID: 37951026
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy.
Winter M; Nait Eldjoudi A; Guette C; Hondermarck H; Bourette RP; Fovez Q; Laine W; Ghesquiere B; Adriaenssens E; Kluza J; Le Bourhis X
Neoplasia; 2023 Dec; 46():100949. PubMed ID: 37956532
[TBL] [Abstract][Full Text] [Related]
7. Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis.
Gao W; Sun L; Gai J; Cao Y; Zhang S
PLoS One; 2024; 19(1):e0297260. PubMed ID: 38227591
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Heterogeneity of Immune Cells in Triple-Negative Breast Cancer at the Single-Cell Level before and after Paclitaxel Chemotherapy.
Zhao H; Lin Z; Zhang Y; Liu J; Chen Q
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762493
[TBL] [Abstract][Full Text] [Related]
9. Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences.
Tayyari F; Gowda GAN; Olopade OF; Berg R; Yang HH; Lee MP; Ngwa WF; Mittal SK; Raftery D; Mohammed SI
Oncotarget; 2018 Feb; 9(14):11677-11690. PubMed ID: 29545929
[TBL] [Abstract][Full Text] [Related]
10. Untargeted LC-MS/MS Metabolomics Study of HO-AAVPA and VPA on Breast Cancer Cell Lines.
Estrada-Pérez AR; García-Vázquez JB; Mendoza-Figueroa HL; Rosales-Hernández MC; Fernández-Pomares C; Correa-Basurto J
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833990
[TBL] [Abstract][Full Text] [Related]
11. A biochemical comparison of the lung, colonic, brain, renal, and ovarian cancer cell lines using 1H-NMR spectroscopy.
Hu C; Liu Z; Zhao H; Wu L; Lian Q; Ma D; Li JV
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32266944
[TBL] [Abstract][Full Text] [Related]
12. Banking on metabolomics for novel therapies in TNBC.
Tripp A; Poulogiannis G
Cell Res; 2022 May; 32(5):423-424. PubMed ID: 35228657
[No Abstract] [Full Text] [Related]
13. Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutamate export and glutaminase.
Choi H; Gupta M; Hensley C; Lee H; Lu YT; Pantel A; Mankoff D; Zhou R
bioRxiv; 2023 Nov; ():. PubMed ID: 38014289
[TBL] [Abstract][Full Text] [Related]
14. TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.
Calistri NL; Liby TA; Hu Z; Zhang H; Dane M; Gross SM; Heiser LM
bioRxiv; 2024 Jun; ():. PubMed ID: 38895265
[TBL] [Abstract][Full Text] [Related]
15. Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence.
Sunassee ED; Deutsch RJ; D'Agostino VW; Castellano-Escuder P; Siebeneck EA; Ilkayeva O; Crouch BT; Madonna MC; Everitt J; Alvarez JV; Palmer GM; Hirschey MD; Ramanujam N
Sci Adv; 2024 Apr; 10(14):eadj7540. PubMed ID: 38579004
[TBL] [Abstract][Full Text] [Related]
16. Integrative multi-omics analysis reveals ortho-topolin riboside exhibits anticancer activity by regulating metabolic pathways in radio-resistant triple negative breast cancer cells.
Ahn J; Lee JW; Nam SM; Kim DK; Cho SK; Choi HK
Chem Biol Interact; 2024 May; 398():111089. PubMed ID: 38823535
[TBL] [Abstract][Full Text] [Related]
17. Amino acids and their roles in tumor immunotherapy of breast cancer.
Xia H; Zhu J; Zheng Z; Xiao P; Yu X; Wu M; Xue L; Xu X; Wang X; Guo Y; Zheng C; Ding S; Wang Y; Peng X; Fu S; Li J; Deng X
J Gene Med; 2024 Jan; 26(1):e3647. PubMed ID: 38084655
[TBL] [Abstract][Full Text] [Related]
18. Unveiling the metabolic landscape of pulmonary hypertension: insights from metabolomics.
Ba H; Guo Y; Jiang Y; Li Y; Dai X; Liu Y; Li X
Respir Res; 2024 May; 25(1):221. PubMed ID: 38807129
[TBL] [Abstract][Full Text] [Related]
19. Metabolomics and triple-negative breast cancer: A systematic review.
Arenas M; Fargas-Saladié M; Moreno-Solé M; Moyano-Femenia L; Jiménez-Franco A; Canela-Capdevila M; Castañé H; Martínez-Navidad C; Camps J; Joven J
Heliyon; 2024 Jan; 10(1):e23628. PubMed ID: 38187259
[TBL] [Abstract][Full Text] [Related]
20. Metabolomics method to comprehensively analyze amino acids in different domains.
Gu H; Du J; Carnevale Neto F; Carroll PA; Turner SJ; Chiorean EG; Eisenman RN; Raftery D
Analyst; 2015 Apr; 140(8):2726-34. PubMed ID: 25699545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
